NCT00083941View on ClinicalTrials.gov

A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Carcinoma, Renal Cell

Interventions

BIOLOGICAL

TroVax

1ml intramuscular injection

BIOLOGICAL

Interleukin-2

Intravenous IL-2

Trial Locations (1)

10032

Columbia Presbyterian Medical Center, New York

Sponsors

Lead Sponsor

Oxford BioMedica

Collaborators (1)

ORION Clinical Services

All Listed Sponsors

collaborator

Columbia University

OTHER

collaborator

ORION Clinical Services

INDUSTRY

lead

Oxford BioMedica

INDUSTRY